New research predicts a positive future for biosimilars

The prospect of reducing treatment costs for payors supports a positive future for biosimilars, according to new research released today.

Corporate advisory firm Results Healthcare today publishes its report looking at the clinical and commercial potential of biosimilars. In the form of a whitepaper, its latest research titled Biosimilars: Prospects and challenges, argues that we have reached an important watershed moment in the clinical and commercial acceptance of biosimilars, creating opportunities for investors to acquire interests and partners in the growing sector.

The analysis predicts that the size of the biosimilars market will expand from $4.4 billion annual sales to $25 billion by 2023 at a compound annual growth rate (CAGR) of 34%.